Cancer Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Cancer
Commercial agreement announced for cancer vaccine product candidate
April 6th, 2004
Prima BioMed Ltd, subsidiary CancerVac, and Biomira Inc. (BIOM) announced a commercial agreement for the development and commercialization of CancerVac's most advanced cancer vaccine product candidate. Biomira will provide CancerVac with access to its licensed exclusive worldwide rights related to a protein called MUC1 in relation to CancerVac's Mannan-MUC1 fusion protein therapeutic vaccine. The Biomira MUC1 patent portfolio includes certain rights to patents held by Cancer Research Technology Limited of London, U.K., which are essential for the development and commercialization of CancerVac's Mannan-MUC1 fusion protein used for cancer...
Source: Cancer Weekly (2004-04-06)
|
